Retifanlimab (1) – Zynyz®
Merkel cell carcinoma, metastatic or recurrent, monotherapy, first-line treatment
Characteristics
| Start date | 01.04.2026 |
|---|---|
| Resolution | 01.10.2026 – active procedure |
| INN | Retifanlimab |
| Brand name | Zynyz® |
| Pharm. company | Incyte Biosciences Germany GmbH |
| G-BA Procedure ID | D-1286 |
| Therapeutic area | Oncological diseases Orphan |
| Reason for procedure | Initial assessment |
Associated procedures
<< List of all resolutions